This conference poster highlights the optimization of CD20 VHH production in mammalian expression systems, focusing on process development for scalable biomanufacturing Using YBL’s YBL-Vega animal-free antibody discovery platform, anti-CD20 VHH antibodies were successfully identified, reformatted into VHH-Fc, and evaluated for their functional performance.

The study demonstrated that the CD20 VHH-Fc format retained strong antigen-binding activity, with successful validation through ELISA, Western blot, immunoblotting, and flow cytometry. The findings also confirmed that antibody expression remained stable during scale-up, highlighting its strong potential for diagnostic, therapeutic research, targeted delivery, and assay development applications.